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RIG-I detects invading viral RNA and activates the
transcription factors NF-kB and IRF3 through the
mitochondrial protein MAVS. Here we show that
RNA bearing 50-triphosphate strongly activates the
RIG-I–IRF3 signaling cascade in a reconstituted
system composed of RIG-I, mitochondria, and
cytosol. Activation of RIG-I requires not only RNA
but also polyubiquitin chains linked through lysine
63 (K63) of ubiquitin. RIG-I binds specifically to K63-
polyubiquitin chains through its tandem CARD
domains in a manner that depends on RNA and
ATP. Mutations in the CARD domains that abrogate
ubiquitin binding also impair RIG-I activation.
Remarkably, unanchored K63-ubiquitin chains,
which are not conjugated to any target protein,
potently activate RIG-I. These ubiquitin chains func-
tion as an endogenous ligand of RIG-I in human cells.
Our results delineate the mechanism of RIG-I activa-
tion, identify CARD domains as a ubiquitin sensor,
and demonstrate that unanchored K63-polyubiquitin
chains are signaling molecules in antiviral innate
immunity.
INTRODUCTION
Innate immunity is an evolutionarily conserved mechanism that
detects and defends against invasion by microbial pathogens,
including viruses, bacteria, and parasites. Detection of path-
ogen-associated molecular patterns (PAMPs) is carried out by
pattern recognition receptors (PRRs) that include membrane-
bound Toll-like receptors (TLRs) and cytosolic receptors such
as retinoic-acid-inducible gene-I (RIG-I)-like receptors (RLRs)
(Akira et al., 2006). In the case of infection by RNA viruses and
some DNA viruses, viral RNAs are the major PAMPs, which are
detected by some TLRs located on the endosomal membrane
(e.g., TLR7) in specialized cells (e.g., plasmacytoid dendriticcells) and RLRs in many types of cells directly infected by
viruses. Recognition of viral RNAs by TLRs and RLRs triggers
signal transduction cascades that culminate in the production
of type I interferons (i.e., IFN-a and IFN-b) and other molecules
that collectively suppress viral replication and assembly.
RLRs include RIG-I, MDA5, and LGP2, all of which contain
a DExD-box RNA helicase domain (Fujita, 2009; Yoneyama
et al., 2004). RIG-I and LGP2 also contain a C-terminal regulatory
domain (RD) that binds to RNA bearing 50-triphosphate
(50-pppRNA) (Hornung et al., 2006; Pichlmair et al., 2006). The
N termini of RIG-I and MDA5, but not LGP2, contain tandem cas-
pase recruitment domains (CARDs) that mediate downstream
signaling. Signaling by both RIG-I and MDA5 requires the essen-
tial adaptor protein MAVS (also known as IPS-1, VISA, or
CARDIF) (Kawai et al., 2005; Meylan et al., 2005; Seth et al.,
2005; Xu et al., 2005). MAVS contains a C-terminal transmem-
brane domain that targets it to the mitochondrial outer
membrane and an N-terminal CARD that is exposed to the
cytosol (Seth et al., 2005). This CARD interacts with the CARDs
of RIG-I, resulting in the activation of MAVS through an unknown
mechanism. MAVS then activates the cytosolic protein kinases
IKK and TBK1, which in turn activate the transcription factors
NF-kB and IRF3, respectively. NF-kB, IRF3, and other transcrip-
tion factors function together in the nucleus to induce the expres-
sion of type I interferons and other antiviral molecules.
Recent studies have revealed a pivotal role of protein ubiquiti-
nation in diverse cell signaling pathways, including those in the
immune system (Bhoj and Chen, 2009). In the RIG-I pathway,
polyubiquitination involving lysine 63 (K63) of ubiquitin is impor-
tant for signaling at steps both upstream and downstream of
MAVS. Upstream of MAVS, K63-linked polyubiquitination of
RIG-I by the RING domain ubiquitin ligase TRIM25 has been
proposed as an important mechanism of RIG-I activation (Gack
et al., 2007). Downstream of MAVS, the activation of TBK1
requires the E2 Ubc5 and K63 polyubiquitination of an unknown
target (Zeng et al., 2009). Several additional ubiquitin ligases
(e.g., Riplet/REUL, RNF125) have been shown to positively or
negatively regulate the RIG-I pathway (Nakhaei et al., 2009).
However, the biochemical mechanisms by which RIG-I and
TBK1 are activated by ubiquitination remain poorly understood.Cell 141, 315–330, April 16, 2010 ª2010 Elsevier Inc. 315
Figure 1. In Vitro Reconstitution of the RIG-I Pathway and Regulation of RIG-I by RNA and Ubiquitination
(A) Purification of RIG-I protein from Sendai virus-infected (+SeV) or untreated (SeV) HEK293T cells stably expressing RIG-I containing a C-terminal Flag
epitope.
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To dissect the signaling mechanisms in the RIG-I pathway, we
establish a cell-free system that mimics viral infection in intact
cells. This in vitro reconstitution system contains recombinant
RIG-I protein, mitochondria, cytosol, RNA, and ubiquitination
enzymes including TRIM25. We demonstrate that 50-pppRNA
and dsRNA, which resemble viral RNA, can activate the entire
RIG-I signaling cascade in vitro, leading to activation of IRF3
and NF-kB. Interestingly, we find that upon incubation with
both RNA and unanchored K63-polyubiquitin (polyUb) chains,
RIG-I is fully activated to cause IRF3 dimerization. We show
that the N terminus of RIG-I, termed RIG-I(N), which contains
tandem CARDs, binds specifically to K63-polyUb chains, and
that this binding is both necessary and sufficient to activate
RIG-I(N). Furthermore, we devise a protocol to isolate endoge-
nous ubiquitin chains associated with RIG-I in a human cell line
and demonstrate that these are unanchored K63-polyUb chains
with potent ability to activate RIG-I. Our results support a model
in which RIG-I binds to two ligands, viral RNA and endogenous
ubiquitin chains, in a sequential manner through the C-terminal
RD and N-terminal CARDs, respectively. The binding of both
ligands is required for full activation of RIG-I.
RESULTS
In Vitro Reconstitution of a RIG-I Signaling Cascade
from RNA to IRF3 Activation
To reconstitute the RIG-I pathway in vitro, we first examined
whether RIG-I isolated from virus-infected cells could cause
IRF3 activation in the presence of mitochondria, which contain
MAVS, and cytosolic extracts, which contain TBK1 and many
other components. A hallmark of IRF3 activation is its dimeriza-
tion, which depends on its phosphorylation by TBK1 and can be
measured by native gel electrophoresis (Yoneyama et al., 2002).
To set up the assay, HEK293T cells stably expressing full-length
RIG-I with a C-terminal Flag tag were infected with Sendai virus
(SeV) or uninfected, then RIG-I was affinity purified (Figure 1A).
Crude mitochondria (P5) and cytosolic extracts (S5) were
prepared from uninfected HEK293T cells by differential centrifu-
gation (Figure 1B), and 35S-labeled IRF3 protein was synthesized
by in vitro translation. As shown in Figure 1C, dimerization of
IRF3 was observed when RIG-I from virus-infected cells was(B) Procedures for isolation of crude mitochondria (P5) and cytosol (S5) by differ
(C) Virus-activated RIG-I induced IRF3 dimerization in vitro. The reconstitution
untreated cells, cytosolic extracts (S5) from uninfected cells, 35S-IRF3, and ATP.
(D) In vitro activation of RIG-I by 50-pppRNA and ubiquitination. His6-tagged RIG
(lower left panel), then incubated with 50-pppRNA (79 nucleotides), ATP, and ub
the reaction mixtures were further incubated with mitochondria (P5) and cytosol (S
ization was analyzed by native gel electrophoresis.
(E) In vitro activation of RIG-I by poly(I:C) and ubiquitination. Similar to (D), excep
enzymes was tested.
(F) The role of 50-triphosphate for RNA to activate RIG-I in vitro. Similar to (D), exc
(SAP).
(G) 50-pppRNA and viral RNA are potent activators of the RIG-I pathway. Total RN
cells, then incubated with RIG-I as in (D), followed by IRF3 dimerization assay (lan
amounts of the RNA (135 nt) (0.07 to 70 nM, at 3-fold increments) were incuba
uninfected cells (lanes 5–11), then IRF3 dimerization assay was performed.
(H) IRF3 dimer shown in (G) was quantified with ImageQuant, then plotted again
See also Figure S1.incubated with mitochondria (P5) and cytosolic extracts (S5) in
the presence of ATP (lane 3). In contrast, RIG-I from mock-
treated cells did not promote IRF3 dimerization (lane 2). The
activation of IRF3 required both cytosol and mitochondria
(lanes 5 and 6). Mitochondria isolated from cells depleted of
MAVS by RNAi could not support IRF3 dimerization (Figure S1A
available online), confirming that MAVS is essential for activating
the downstream pathway in this in vitro assay. When RIG-I was
isolated from cells depleted of TRIM25 by RNAi, its ability to
promote IRF3 dimerization in the in vitro assay was greatly
reduced (Figure S1B), supporting an important role of TRIM25
in RIG-I activation. As we have shown recently, mitochondria
isolated from virus-infected cells activated IRF3 in the absence
of RIG-I (Figure 1C, lane 1) (Zeng et al., 2009).
Transfection of cells with synthetic RNAs, such as the dsRNA
analog poly(I:C) and 50-pppRNA, potently induces IRF3 dimeriza-
tion. To test if RNA could activate the entire RIG-I pathway in vitro,
we expressed and purified full-length RIG-I from insect cells (Sf9;
Figure 1D, lower left) and incubated it with ATP and a 79 nucleo-
tide (79 nt) 50-pppRNA (Figure S1C). This RNA strongly induced
IFN-b when transfected into HEK293-IFN-b-luciferse reporter
cells (Figure S1D). However, incubation of this RNA with the
recombinant RIG-I protein did not cause IRF3 dimerization in
the reconstituted system (Figure 1D, lane 1 in lower right panel).
As ubiquitination has been shown to be important in the RIG-I
pathway, we incubated RIG-I with E1, Ubc5c (E2), TRIM25 (E3),
and ubiquitin together with ATP and RNA. Remarkably, this
condition caused RIG-I to activate the entire pathway, resulting
in IRF3 dimerization (Figure 1D, lane 3 in lower right panel).
A K270A mutation in the ATPase domain of RIG-I, which abro-
gates the ability of RIG-I to induce interferons in vivo (Yoneyama
et al., 2004), also abolished its ability to induce IRF3 dimerization
in vitro. Poly(I:C) stimulated IRF3 dimerization in this reconsti-
tuted system in a manner dependent on ubiquitin, E1, Ubc5c,
TRIM25, and RIG-I (Figure 1E). Activation of RIG-I was also
observed with another 50-pppRNA containing 135 nucleotides
(135 nt) (Figure 1F). Dephosphorylation of the 50-pppRNAs with
shrimp alkaline phosphatase (SAP) destroyed their ability to acti-
vate IRF3 in vitro (Figure 1F) and IFN-b induction in HEK293T cells
(Figure S1D). In contrast, treatment of poly(I:C) with SAP did not
inhibit its activity, consistent with the previous report that thisential centrifugation.
reaction contained mitochondria (P5), RIG-I isolated from virus-infected or
Dimerization of IRF3 was analyzed by native gel electrophoresis.
-I (wild-type or WT) or its ATPase mutant (K270A) was purified from Sf9 cells
iquitination enzymes as outlined in the diagram. After incubation, aliquots of
5) from uninfected cells together with 35S-IRF3 and ATP, and then IRF3 dimer-
t that poly(I:C) was used and the dependency on ubiquitin and ubiquitination
ept that the RNA was pretreated with or without shrimp alkaline phosphatase
A was extracted from HEK293T cells from viral-infected or untreated HEK293T
es 1–3). To measure the potency of 50-pppRNA in RIG-I activation, increasing
ted with RIG-I in the presence (lanes 12–18) or absence of cellular RNA from
st the concentration of 50-pppRNA.
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Figure 2. K63 Polyubiquitination Is Essential for RIG-I Activation
(A) Ubc5 and Ubc13/Uev1a activate RIG-I in vitro. RIG-I was incubated with E1, different E2s as indicated, TRIM25, ubiquitin, RNA, and ATP, followed by IRF3
dimerization assay as described in Figure 1D. The E2 proteins (2 mg) were analyzed by Coomassie blue staining (lower panel).
(B) Ubc5 and Ubc13 are required for viral activation of MAVS in the mitochondria. U2OS cells stably integrated with tetracycline-inducible shRNA againstUbc5b/c
and Ubc13 were treated with or without tetracycline (Tet). After viral infection for the indicated time, mitochondrial fraction (P5) was prepared and the MAVS
activity was measured by IRF3 dimerization assay.
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dsRNA analog activates RIG-I and MDA5 in a manner indepen-
dent of 50-triphosphate (Kato et al., 2008). As expected, the
DNA poly(dI:dC) did not activate the RIG-I pathway in vitro or in
cells (Figure 1F and Figure S1D). In vitro reconstitution of the
RIG-I pathway also led to site-specific phosphorylation of IRF3
and IkBa (Extended Results and Figures S1E–S1G).
To determine if RIG-I could be activated by naturally occurring
viral RNA, we incubated purified RIG-I protein with total RNA
from HEK293T cells infected with Sendai virus. Indeed, RNA
from virus-infected but not mock-treated cells stimulated RIG-I
to activate IRF3 (Figure 1G, lanes 1–3). To estimate the sensitivity
of 50-pppRNA detection by RIG-I, we incubated RIG-I with
different amounts of 50-pppRNA in the presence or absence of
HEK293T cellular RNA (Figure 1G, lanes 4–18). The half-maximal
effective concentration (EC50) of the 5
0-pppRNA was estimated
at 1.2 nM and 0.4 nM in the absence and presence of the cellular
RNA, respectively (Figure 1H). It is not clear how the cellular RNA
enhances the potency of 50-pppRNA, but one possibility is that
these RNAs reduce the nonspecific loss of very small amounts
of 50-pppRNA in the reactions. In any case, the fact that the pres-
ence of a large excess of cellular RNA does not interfere with the
specific recognition of 50-pppRNA by RIG-I underscores the
remarkable specificity of viral RNA detection by RIG-I. Assuming
that the cytoplasm of a human cell has a volume of500 mm3, we
estimated that less than 20 molecules of viral RNA in a cell
(equivalent to 0.07 nM) are sufficient to trigger detectable
IRF3 dimerization. Thus, our in vitro reconstitution recapitulates
the entire RIG-I pathway with exquisite sensitivity and specificity
for 50-pppRNA (see Discussion).Ubc5 and Ubc13 Are Required for the Activation
of RIG-I and MAVS
Ubc5 is a family of E2s comprising highly homologous isoforms
(Ubc5a, b, and c; putative Ubc5d in human) that catalyze the
synthesis of polyUb chains linked through various lysines of
ubiquitin, including K63 (Xu et al., 2009). In contrast to Ubc5,
the E2 complex consisting of Ubc13 and Uev1A is highly specific
in synthesizing K63-polyUb chains (Deng et al., 2000; Hofmann
and Pickart, 1999). To determine the E2 involved in RIG-I activa-
tion, we examined a panel of E2s for their ability to stimulate
RIG-I in the presence of TRIM25 and RNA (Figure 2A). The
Ubc5 isoforms (Ubc5a, b, and c) and Ubc13/Uev1A were
capable of stimulating RIG-I to promote IRF3 dimerization. In
contrast, Ubc3, Ubc7, and E2-25K had no activity (Figure 2A),
despite the ability of these E2s to form thioesters with ubiquitin
(data not shown; see also Zeng et al., 2009). To test if Ubc5
and/or Ubc13 are involved in the activation of MAVS by RIG-I,
we established human osteosarcoma U2OS cell lines stably
integrated with tetracycline-inducible shRNA vectors targeting(C) K63 of ubiquitin is essential for RIG-I activation in vitro. RIG-I and IRF3 activati
panel) as the E2 and various ubiquitin mutants as indicated. KO, lysine-less mut
(D) K63 polyubiquitination is essential for viral activation of MAVS in the mitocho
endogenous ubiquitin genes and a rescue expression vector for wild-type or K63
After infection by Sendai virus, mitochondria (P5) were prepared to measure MAV
blotting (lower panels). The HA antibody detects HA-Ub(WT) or HA-Ub(K63R) ex
See also Figure S2.both Ubc13 and two isoforms of Ubc5 (Ubc5b and c) (Xu et al.,
2009). As shown in Figure 2B, the mitochondria from the cells
depleted of Ubc13, Ubc5b, and Ubc5c lost the ability to activate
IRF3. These results suggest that Ubc5a and Ubc5d, which are
not targeted by the Ubc5 shRNAs, play a minor role in IRF3 acti-
vation in U2OS cells. RNAi of Ubc13 or Ubc5 alone partially in-
hibited the IRF3-stimulatory activity of the mitochondria from
virus-infected cells (Figure S2A; Figure S3 in Zeng et al., 2009).
These results suggest that both Ubc5 and Ubc13 are involved
in the activation of MAVS in the mitochondria by RIG-I in
response to viral infection.K63 Polyubiquitination Is Essential for the Activation
of RIG-I and MAVS
To determine if K63 of ubiquitin is required for RIG-I activation in
the in vitro system, we incubated various ubiquitin lysine mutants
with RIG-I in the presence of RNA, ATP, E1, TRIM25, and Ubc5c
or Ubc13/Uev1A. The reaction mixture was then incubated with
the mitochondrial fraction (P5) to activate MAVS. The activated
mitochondria were isolated and then tested for their ability to
stimulate IRF3 dimerization in the presence of cytosolic extracts
(Figure 2C). The ubiquitin proteins containing a lysine at position
63 (wild-type, K48R and K63-only) were capable of activating
RIG-I, whereas those containing a substitution at K63 (K63R,
K48-only, KO, and methylated ubiquitin) had no activity (Fig-
ure 2C; see Figure S2C for an illustration of ubiquitin mutants).
Interestingly, although Ubc5c and TRIM25 catalyze the synthesis
of polyUb chains from K63R (Figure S2D, lane 2), these chains did
not stimulate RIG-I (Figure 2C, lane 2), indicating that K63-polyUb
chain synthesis is specifically required for RIG-I activation in vitro.
To investigate the role of K63 polyubiquitination in the activa-
tion of MAVS in cells, we used recently developed U2OS cell
lines in which endogenous ubiquitin is replaced with wild-type
or K63R mutant of ubiquitin through a tetracycline-inducible
strategy (Xu et al., 2009). As shown in Figure 2D, depletion of
endogenous ubiquitin severely impaired the ability of the mito-
chondria to promote IRF3 dimerization, but this activity was
rescued by the expression of the wild-type ubiquitin transgene.
In contrast, when the endogenous ubiquitin was replaced with
the K63R mutant, the mitochondria isolated from these cells
failed to activate IRF3 in the in vitro assay, strongly suggesting
that K63 polyubiquitination is essential for viral activation of
MAVS in the mitochondria.K63-Polyubiquitin Chains Activate RIG-I through
Its N-terminal CARDs
The N terminus of RIG-I contains tandem CARDs, which, when
overexpressed in mammalian cells, constitutively activate IRF3
(Yoneyama et al., 2004). To determine if this N-terminal fragmenton assays were performed using Ubc13/Uev1a (upper panel) or Ubc5c (middle
ant; MeUb, methylated ubiquitin.
ndria. U2OS cells stably integrated with tetracycline-inducible shRNA against
R mutant of ubiquitin were grown in the presence or absence of tetracycline.
S activation. The expression of MAVS and ubiquitin was analyzed by immuno-
pressed from the transgene rescue vector.
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Figure 3. Activation of RIG-I N Terminus
by K63-Polyubiquitin Chains
(A) Depiction of RIG-I functional domains.
(B)Purification of recombinant GST-RIG-I(N) protein
from E. coli.
(C) Activation of RIG-I(N) by ubiquitination. GST or
GST-RIG-I(N) was incubated with ubiquitination
reaction (E1, Ubc5, TRIM25, and ubiquitin) and/or
poly(I:C) as indicated, then an aliquot of the reac-
tion was further incubated with mitochondria (P5)
and cytosol (S5) to measure IRF3 dimerization.
(D) K63-polyUb chain synthesis, but not ubiquiti-
nation of RIG-I(N), is required for RIG-I activation
in vitro. Ubiquitination reactions containing dif-
ferent combinations of E2s and E3s as indicated
were carried out before N-ethylmaleimide (NEM)
was added to inactivate E1 and E2s. An aliquot
of the reaction mixture was incubated with GST-
RIG-I(N), then further incubated with mitochondria
(P5) and cytosol (S5) to measure IRF3 dimeriza-
tion. Another aliquot of the reaction was analyzed
by immunoblotting with a ubiquitin antibody (lower
panel). SCFb-TrCP2: an E3 complex containing
Skp1, Cul1, Rbx1, and b-TrCP2; LUBAC: an E3
complex containing HOIL-1L and HOIP.
(E) Similar to (D), except that ubiquitination
reactions were carried out in the presence of
Ubc5c, TRIM25, and various ubiquitin mutants
as indicated.
See also Figure S3.[RIG-I(N), see Figure 3A] could activate IRF3 in vitro, we ex-
pressed the protein in E. coli and purified it to near
homogeneity (Figure 3B). When the protein was incubated with
mitochondria and cytosolic extracts, it did not promote IRF3
dimerization (Figure 3C, lane 2). However, when the incubation
mixtures contained ubiquitination components, including E1,320 Cell 141, 315–330, April 16, 2010 ª2010 Elsevier Inc.Ubc5c, TRIM25, and ubiquitin, robust
IRF3 dimerization was detected even in
the absence of RNA (lane 3).
To determine if ubiquitination of RIG-
I(N) is required for IRF3 activation in the
in vitro system, we carried out a ubiquiti-
nation reaction in the presence of
different pairs of E2 and E3 and then
treated the reaction mixture with the
chemical N-ethylmaleimide (NEM), which
alkylates the active site cysteine of E1
and E2. The reaction mixtures were then
incubated with GST-RIG-I(N) before
further incubation with the mitochondrial
and cytosolic fractions to measure IRF3
dimerization (Figure 3D). Under these
conditions, RIG-I(N) was not ubiquiti-
nated because E1 and E2 had been inac-
tivated by NEM. Remarkably, when
TRIM25 or another RING domain E3
TRAF6 was incubated with either
Ubc13/Uev1A or Ubc5c, robust IRF3
dimerization was detected (lanes 2–5).When K48 polyUb chains were synthesized by Ubc3 and an E3
complex consisting of Skp1, Cul-1, Rbx1, and bTrCP2 (SCF-
bTrCP2), these chains did not activate the RIG-I pathway. Simi-
larly, linear polyUb chains generated by Ubc5c and an E3
complex consisting of HOIP-1 and HOIL-1L (termed LUBAC)
did not lead to significant IRF3 dimerization. To further test if
ubiquitin chains of other linkages could support IRF3 dimeriza-
tion, we used a panel of ubiquitin mutants harboring a single
lysine (Figure 3E). Although all the ubiquitin mutants were
capable of forming polyUb chains in the presence of Ubc5c
and TRIM25, the only mutants capable of supporting IRF3 acti-
vation were those containing a lysine at position 63 (K63 only
and His6-K63 only). Collectively, these results clearly demon-
strate that polyUb chains containing the K63 linkage, but not
other linkages, specifically activate the RIG-I pathway. We also
found that unanchored polyUb chains, but not ubiquitinated
TRIM25, mediate RIG-I activation (Extended Results and
Figure S3).Short, Unanchored, K63-Linked Ubiquitin Chains
Activate RIG-I
To determine if short ubiquitin chains are capable of activating
RIG-I, we incubated GST-RIG-I(N) with a ubiquitin polymer
containing four units of ubiquitin linked through K63 (K63-Ub4;
Figure 4A). Strikingly, incubation of GST-RIG-I(N) with K63-Ub4
led to robust activation of IRF3 in this assay (lane 2), whereas
GST-RIG-I(N) or K63-Ub4 alone had no activity (lanes 1 and 3).
We then tested a panel of ubiquitin chains of different lengths
and linkages for their ability to activate RIG-I(N) (Figure 4B). Inter-
estingly, K63-Ub chains containing more than two ubiquitin
moieties potently activated RIG-I(N) (Figure 4B, lanes 3–8).
K63-Ub2 had very weak activity (lane 2), whereas monomeric
ubiquitin and K48-linked ubiquitin chains were inactive (lane 1;
lanes 11–14). Ub4 containing mixed linkages of K48 and K63
also had greatly reduced activity (lanes 9–10). We then carried
out titration experiments to quantify the relative potency of
different ubiquitin chains in the activation of RIG-I(N) (Figures
4C and 4E). Similar titration experiments were also carried out
using full-length RIG-I in the presence of 50-pppRNA (Figures
4D and 4F). Among the ubiquitin chains tested, K63-Ub4 was
the most potent activator, with an EC50 of 25 nM for RIG-I(N)
activation. The potency of K63-Ub3 was about 27-fold less
(EC50 z 680 nM), whereas K63-Ub2 was nearly inactive even
at the highest concentration (1 mM). Ubiquitin, K48-Ub3, and
linear-Ub3 were inactive at all the concentrations tested. These
results demonstrate that short, unanchored K63-ubiquitin chains
containing at least three ubiquitin moieties are potent and
specific activators of RIG-I.The Tandem CARDs of RIG-I Bind to K63-Ubiquitin
Chains
The potent activation of RIG-I(N) by K63-ubiquitin chains implies
that the N terminus of RIG-I binds to these chains. Indeed,
GST-RIG-I(N) was able to pull down K63-Ub3, but not
K48-Ub3 or linear Ub3 (Figure 5A). Both CARDs are required
for ubiquitin binding because the fragments containing residues
11–200 or 2–180 of RIG-I failed to bind K63-Ub4 or activate IRF3
(Figures 5B and 5C; see also Figures S5A and S5B). We also
generated a RIG-I(N) protein containing a T55I mutation, which
was previously shown to render RIG-I defective in interferon
induction (Sumpter et al., 2005). Interestingly, T55I mutation
severely impaired the ability of RIG-I(N) to bind K63-Ub4 and
activate IRF3 (Figure 5C, lane 10), suggesting that the signalingdefect of this mutant may be due to its failure to bind
K63-ubiquitin chains.
To determine if ubiquitin chain binding induces oligomerization
of RIG-I(N), we incubated RIG-I(N) with K63-Ub4 and then
performed gel filtration analysis using Superdex-200. K63-Ub4
and RIG-I(N) have predicted molecular masses of 30 and
24 kDa, respectively; however, they formed an active complex
with an apparent molecular mass of200 kDa (Figure 5D). When
each protein alone was fractionated on the same column,
K63-Ub4 and RIG-I(N) eluted at positions corresponding to
25 and 50 kDa, respectively. These results suggest that the
binding of K63-Ub4 to RIG-I(N) promotes the formation of an
oligomeric complex (e.g., a tetramer).
Full-length RIG-I Binds to K63-Ubiquitin Chains
in a Manner that Depends on RNA and ATP
As full-length RIG-I is regulated by RNA binding and ATP hydro-
lysis, we tested its binding to K63-ubiquitin chains in the
presence or absence of RNA and ATP. Immunoprecipitation of
His8-RIG-I-Flag led to coprecipitation of K63-Ub4 and long
K63-polyUb chains in the presence of 50-pppRNA and ATP
(Figure 5E, lanes 2 and 6). This binding was lost when the RNA
was absent or when EDTA was added to chelate Mg2+, which
is required for ATP binding. Two different mutations that
abrogate the ATPase activity of RIG-I, K270A and D372N, also
disrupted the ability of RIG-I to bind K63 polyUb (Figure 5F). To
determine if RIG-I binds to RNA and K63 polyUb in a sequential
manner, we incubated RIG-I with 50-pppRNA or K63 polyUb in
reciprocal orders (Figure 5G). If RIG-I was preincubated with
50-pppRNA in the first step and then with K63 polyUb in the
second step, it was capable of activating IRF3 dimerization in
the reconstitution assay (lane 4). In contrast, if RIG-I was prein-
cubated with K63 polyUb first, then immunoprecipitated to
remove unbound polyUb, its subsequent incubation with
50-pppRNA failed to activate it (lane 6). Thus, the binding of
RIG-I to RNA precedes its binding to K63 polyUb.
Binding of K63-Ubiquitin Chains Is Necessary
for RIG-I Activation
Previous studies have shown that RIG-I is ubiquitinated at K172
and that a mutation of this residue (K172R) impairs its ability to
induce IFN-b (Gack et al., 2007). Consistent with an important
role of K172 in RIG-I activation, we found that GST-RIG-I(N) con-
taining the K172R mutation failed to activate IRF3 in the in vitro
reconstitution assay (Figure 6A, lanes 4–6). A GST-RIG-I(N)
protein containing mutations at six lysines (K99, 169, 172, 181,
190, 193; herein referred to as 6KR) was also inactive (lanes
10–12), but this activity was rescued by keeping the lysine at
position 172 (K172-only; lanes 7–9). Interestingly, the K172R,
6KR, and T55I mutants were greatly compromised in their ability
to bind K63 polyUb, whereas K172-only was fully capable of
binding to these chains (Figure 6B). These results show that
the IRF3-activating function of RIG-I correlates well with its
ubiquitin-binding activity.
To determine if ubiquitination or ubiquitin binding of RIG-I is
important for its activation in cells, we expressed GST-RIG-I(N)
and various mutants in HEK293-IFN-b-luciferase reporter cells
(Figure 6C), then pulled down these proteins with glutathioneCell 141, 315–330, April 16, 2010 ª2010 Elsevier Inc. 321
Figure 4. Short, Unanchored K63-Ubiquitin Chains Potently Activate RIG-I
(A) K63-Ub4 activates RIG-I(N). GST-RIG-I(N) (0.2 mM) was incubated with or without K63-Ub4 (0.3 mM), followed by IRF3 dimerization assay as outlined.
(B) K63, but not K48, ubiquitin chains activate RIG-I(N). Ubiquitin chains of defined lengths and linkages were incubated with GST-RIG-I(N), then IRF3 dimerization
assay was carried out as in (A). The quality of the ubiquitin chains was evaluated by immunoblotting (lower panel) or silver staining (see Figure S4).
(C) K63-ubiquitin chains potently activate RIG-I(N) in a chain length- and linkage-dependent manner. Different concentrations of Ub chains (0.01–1 mM) or ubiq-
uitin (0.1–10 mM) were tested for RIG-I(N) activation using the IRF3 dimerization assay.
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Sepharose (Figure 6D). To distinguish ubiquitin chains covalently
conjugated to RIG-I from those noncovalently associated with
RIG-I, the Sepharose beads were washed with either phos-
phate-buffered saline (PBS) or a more stringent buffer containing
0.1% SDS and 1% deoxycholate (RIPA; Figure 6D). Immunoblot-
ting with a GST antibody showed that whereas the wild-type
GST-RIG-I(N) was conjugated by ubiquitin chains, no apparent
ubiquitination of the mutants, including K172R and K172-only,
was detected (Figure 6D, lower panel). Immunoblotting of the
pull-down proteins with a ubiquitin antibody showed an inter-
esting difference depending on the wash buffers (upper panel).
Whereas GST-RIG-I(N) containing K172-only was able to pull
down polyUb chains from the cells when the beads were washed
with PBS (lane 9), these chains were largely washed away with
the RIPA buffer (lane 4), indicating that this mutant was defective
in ubiquitination but retained the ability to bind polyUb chains.
Because GST-RIG-I(N)-K172-only was active in inducing IFN-b
(Figure 6C), these results suggest that polyUb binding by RIG-I
is responsible for its function. The other RIG-I mutants, including
K172R, 6KR, and T55I, were unable to bind ubiquitin chains in
cells, consistent with their inability to induce IFN-b.
To further evaluate whether RIG-I ubiquitination is required for
its function, we treated GST-RIG-I(N) isolated from HEK293T
cells with a deubiquitination enzyme (DUB), which contains the
OTU domain of the Crimean Congo hemorrhagic fever virus
(CCHFV) large (L) protein (Figure 6E) (Frias-Staheli et al., 2007;
Xia et al., 2009). The viral OTU (vOTU) can cleave polyUb chains
from target proteins as well as unanchored polyUb chains. In
contrast, another DUB, isopeptidase T (IsoT), only cleaves unan-
chored polyUb chains (Reyes-Turcu et al., 2006). Following
treatment with vOTU or IsoT, GST-RIG-I(N) was tested for its
ability to activate IRF3 in the in vitro reconstitution assay. Unlike
GST-RIG-I(N) expressed in E. coli, which does not have the ubiq-
uitin system, the same protein expressed in HEK293T cells was
able to activate IRF3 without preincubation with ubiquitin chains
(Figure 6E, bottom panel), probably because RIG-I(N) isolated
from human cells is already bound to endogenous polyUb chains
(e.g., lane 9 in Figure 6D). Interestingly, although vOTU removed
most of the ubiquitin chains from GST-RIG-I(N) (Figure 6E, lanes
6 and 9 in upper panel), the deubiquitinated RIG-I protein was as
active in causing IRF3 dimerization as the protein that was mock
treated (lanes 1–4 and 9–12, lower panel). These results suggest
that ubiquitination of the RIG-I CARDs may be dispensable for its
activity.
Unanchored K63-Polyubiquitin Chains Isolated
from Human Cells Are Potent Activators of RIG-I
In Figure 6E, we noted that IsoT treatment did not remove much
of the polyUb chains from GST-RIG-I(N) (lane 5 in upper panel),
indicating that RIG-I(N) protects the ubiquitin chains from
degradation by IsoT (see Extended Results and Figure S6). The
protection of polyUb by RIG-I(N) offers an opportunity to detect
the otherwise labile ubiquitin chains in cells but poses another
challenge of how to release these chains while preserving their
functions. We devised a protocol to isolate the RIG-I-bound(D) Similar to (C), except that full-length His6-RIG-I and 5
0-pppRNA were used in
(E and F) IRF3 dimers in (C) and (D), respectively, were quantified using ImageQubiquitin chains from HEK293T cells by employing two strategies
(Figure 7A). First, we lysed the cells in the presence of NEM to
inactivate most of the deubiquitination enzymes. Ubiquitin
contains no cysteine, therefore evading modification by NEM.
Second, as ubiquitin is known to be relatively stable at high
temperatures, we heated the RIG-I(N):polyUb complex at
different temperatures to identify a condition that denatures
RIG-I(N) but preserves the structure and function of ubiquitin
chains. Following centrifugation that precipitates denatured
protein aggregates, the supernatant is expected to contain
polyUb chains and can be tested for its ability to activate IRF3
in the presence of fresh RIG-I(N). Because GST-RIG-I(N)-K172-
only appears to capture more polyUb chains, we expressed
this protein in HEK293T cells (Figure 7B). In control experiments,
we incubated GST-RIG-I(N)-K172-only protein with K63-polyUb
chains in vitro, carried out GST pull-down, and then heated the
complex (lanes 1–6). Five minutes of heating at 70C–80C
was sufficient to inactivate the RIG-I protein (lane 1, 3, and 5)
and release polyUb chains into the supernatant, which were
capable of activating IRF3 when supplied with fresh GST-RIG-
I(N) (lane 2, 4, and 6). When the GST-RIG-I(N) protein expressed
in HEK293T cells was heated at 70C, it was still capable of acti-
vating IRF3 in the absence of fresh RIG-I(N) (lane 7), indicating
that the activated RIG-I(N) complex was resistant to NEM and
70C treatment. However, raising the temperatures to 75C
and 80C inactivated the GST-RIG-I(N) protein (lanes 9 and 11).
Strikingly, the supernatant containing polyUb chains released
from the RIG-I(N) complex at the high temperatures were
capable of activating IRF3 when supplied with fresh
GST-RIG-I(N) (lanes 10 and 12).
To determine whether the supernatant of the heated
GST-RIG-I(N) complex contained unanchored polyUb chains
and whether these chains were responsible for activating the
RIG-I pathway, we performed two sets of experiments. First,
we incubated the supernatant with E1 to determine if the endog-
enous ubiquitin chains could form thioesters with E1. Indeed, in
the presence of E1 and ATP, substantial fractions of both
synthetic and endogenous ubiquitin chains formed thioesters
that were sensitive to reduction by b-mercaptoethanol, indi-
cating that they contained unanchored C termini (Figure S7A).
Second, we incubated the endogenous ubiquitin chains with
IsoT and then measured their activity in the IRF3 dimerization
assay (Figure 7C). Importantly, the IsoT treatment completely
abolished the ability of the supernatant to activate IRF3 in the
presence of GST-RIG-I(N) (lane 8). However, if we reversed the
order by incubating the supernatant with GST-RIG-I(N) first
and then with IsoT, IRF3 dimerization was observed (lane 9).
Parallel control experiments show that unanchored K63-polyUb
chains were sensitive to IsoT treatment but became resistant
after preincubation with GST-RIG-I(N) (lanes 2–5). To directly
visualize unanchored polyUb chains associated with the
GST-RIG-I(N) complex isolated from HEK293T cells, the heated
supernatants treated with and without IsoT were analyzed by
immunoblotting with a ubiquitin antibody (Figure 7C, right panel).
Several bands in the range of 40–75 kDa, most prominently thelieu of RIG-I(N) in the reactions.
uant, then plotted against the concentration of Ub or Ub chains.
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Figure 5. RIG-I CARDs Bind K63-Ubiquitin Chains, and This Binding in Full-Length RIG-I Is Regulated by RNA and ATP
(A) RIG-I(N) binds specifically to K63-ubiquitin chains. GST or GST-RIG-I(N) was incubated with Ub3 containing K63, K48, or linear linkage, then pulled down with
glutathione Sepharose, followed by immunoblotting. Input represents 10% of Ub3 used in the pull-down experiments.
(B) Diagram of RIG-I N terminus containing the tandem CARDs and various deletion and point mutants. The table on the right summarizes the results in (C).
(C) Both CARDsof RIG-I are required for polyUb binding and IRF3 activation. GST-RIG-I(N) and various mutants were incubated with K63-Ub4.One microliter aliquot
of eachmixturewas used for IRF3 dimerization assay (upper panel), and the remainder was pulled down withglutathione Sepharose followed by immunoblottingwith
a Ub antibody (middle panel). The GST-RIG-I(N) and the mutant proteins (2 mg each) were analyzed by Coomassie blue staining (lower panel). See also Figure S5.
(D) RIG-I(N) and K63-Ub4 form an active high-molecular-weight complex. RIG-I(N) was incubated with K63-Ub4 and then the mixture was fractionated on Super-
dex-200. Aliquots of the fractions were assayed for their ability to stimulate IRF3 dimerization, whereas other aliquots were subjected to immunoblotting with
antibodies against RIG-I and ubiquitin. K63-Ub4 or RIG-I(N) alone was also analyzed by gel filtration on the same column (lower two panels).
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40 kDa band, disappeared in the IsoT-treated sample, indicating
that these are unanchored ubiquitin polymers containing
approximately 5–10 ubiquitin moieties. However, most of the
high-molecular-weight bands remained resistant to IsoT treat-
ment, suggesting that they represent ubiquitin chains conju-
gated to some protein targets. Because the IsoT treatment
completely abolished the activity of the heat supernatant to
promote IRF3 dimerization (Figure 7C, lane 8 on left panel), the
high-molecular-weight ubiquitin conjugates remaining after
IsoT treatment apparently did not contribute to RIG-I activation.
To determine if the endogenous unanchored polyUb chains
are linked through K63 of ubiquitin, we treated the heat-resistant
supernatant with the K63-specific deubiquitination enzyme
CYLD. This treatment markedly diminished the ability of the
supernatant to activate RIG-I (Figure 7D, left panel). CYLD
also destroyed the ubiquitin chains with molecular masses in
the range of 40–75 kDa, which could be detected with an anti-
body specific for the K63-ubiquitin linkage (Figure 7D, right
panel).
TRIM25 and CYLD have previously been shown to be impor-
tant for the activation and inactivation of the RIG-I pathway,
respectively (Friedman et al., 2008; Gack et al., 2007; Zhang
et al., 2008). To determine if these enzymes are involved in the
synthesis and disassembly of endogenous K63-ubiquitin chains,
we used siRNA to knock down the expression of TRIM25 or
CYLD in HEK293T cells, then isolated the endogenous ubiquitin
chains as outlined in Figure 7A. Immunoblotting experiments
showed that depletion of TRIM25 diminished, whereas depletion
of CYLD enhanced, the production of endogenous polyUb
chains, which in turn activated IRF3 (Figure 7E).
To evaluate the potency of endogenous polyUb chains in acti-
vating RIG-I, we carried out titration experiments using different
amounts of heat-resistant supernatants isolated from HEK293T
cells (Figure 7F). The amount of endogenous K63-Ub6 was
estimated by comparing to synthetic K63-Ub6 using semiquan-
titative immunoblotting (Figure S7B). Because K63-Ub6 is the
dominant species of endogenous polyUb chains, its concentra-
tion was used to calculate the EC50 for stimulating RIG-I.
Remarkably, the EC50 for the endogenous ubiquitin chains was
estimated to be approximately 50 picomolar (pM), indicating
that these ubiquitin chains are highly potent ligands of RIG-I.
Finally, we examined whether viral infection induces the
formation of polyUb chains associated with full-length RIG-I in
cells (Figure S7C). HEK293T cells expressing RIG-I-Flag were
infected with Sendai virus or mock treated, and then the RIG-I
complex was immunoprecipitated and heated at 76C to release
polyUb chains. The heat supernatant prepared from the virus-
infected cells, but not mock-treated cells, stimulated IRF3
dimerization in the presence of RIG-I(N). This activity was dimin-
ished by IsoT treatment (Figure S7D), indicating that the super-(E) Full-length RIG-I binds to ubiquitin chains in a manner that depends on 50-pp
chains in the presence or absence of 50-pppRNA (135 nt), ATP, or EDTA. Follow
detected with an antibody against Ub or RIG-I. The asterisk indicates a nonspe
(F) Similar to (E), except that RIG-I ATPase mutants (K270A and D372N) we
nonspecific band.
(G) Sequential binding of RIG-I to RNA and polyUb leads to IRF3 activation. His8-
immunopurified using a Flag antibody. The purified RIG-I was incubated with K63-natant contained unanchored polyUb chains. It should be noted
that the activity associated with full-length RIG-I was much lower
than that associated with RIG-I(N) because the activation of
full-length RIG-I is limited by its accessibility to viral RNA (see
Discussion). Nevertheless, given the potency of 50-pppRNA
and unanchored polyUb chains in activating RIG-I, small
amounts of viral RNA and endogenous ubiquitin chains are likely
to be sufficient to trigger the RIG-I signaling cascade.
In sum, the results presented herein demonstrate that (1) the
unanchored K63-ubiquitin chains are present in human cells;
(2) they are bound and protected by RIG-I; and (2) they are potent
activators of the RIG-I pathway. We propose that sequential
binding of RIG-I to RNA and unanchored K63-polyUb chains
leads to full activation of RIG-I, which in turn activates MAVS
and downstream signaling cascades (Figure 7G).
DISCUSSION
In this report, we demonstrate that RNA with characteristics
of viral RNA (50-pppRNA and dsRNA) can activate the RIG-I
pathway in vitro in a reconstitution system with exquisite speci-
ficity and sensitivity. To our knowledge, this is the first in vitro
reconstitution of an immune signaling cascade from a microbial
ligand (viral RNA) to activation of a transcription factor (IRF3). Our
success in reconstituting the RIG-I pathway in vitro is beneficiary
of at least three previous discoveries that (1) RNAs containing
50-triphosphate are direct functional ligands of RIG-I (Hornung
et al., 2006; Pichlmair et al., 2006); (2) mitochondria containing
MAVS are essential for RIG-I signaling (Seth et al., 2005); and
(3) ubiquitination is important for RIG-I activation (Gack et al.,
2007). The in vitro reconstitution of the RIG-I pathway sets the
stage for delineating the biochemical mechanism of RIG-I activa-
tion and subsequent steps of downstream signaling. Testimonial
to the power of this in vitro system are the discoveries revealed in
this study that the tandem CARDs of RIG-I represent a new class
of ubiquitin-binding domain with specificity for K63-polyUb
chains and that unanchored K63-polyUb chains are potent
intracellular signaling molecules that activate the RIG-I pathway.
Specificity and Sensitivity of Viral RNA Detection
by RIG-I
A major determinant that distinguishes viral RNA from the host
RNA in mammalian cells is the presence of 50-triphosphate in
viral RNA but not in host RNA (Fujita, 2009). 50-pppRNA is gener-
ated in the course of RNA replication by viral RNA polymerases.
However, RIG-I may have very limited access to viral 50-pppRNA
for the following reasons: (1) viral RNA replication normally
occurs within a membrane compartment (e.g., vesicles) that is
sequestered from the cytosolic immune sensors such as RIG-I;
(2) some viruses such as influenza replicate in the nucleus ratherpRNA and ATP. His8-RIG-I-Flag was incubated with K63-Ub4 or K63-polyUb
ing immunoprecipitation with a Flag antibody, the precipitated proteins were
cific band.
re also tested for binding to K63-polyUb chains. The asterisk indicates a
RIG-I-Flag was incubated with 50-pppRNA or K63-polyUb in the first step, then
polyUb or 50-pppRNA in the second step, followed by IRF3 dimerization assay.
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Figure 6. Polyubiquitin Binding Is Required for RIG-I Activation
(A) Mutations at K172 and T55 impair RIG-I(N) activation in vitro. GST-RIG-I(N) and the indicated mutants were expressed and purified from E. coli, then incubated
with K63-Ub4, followed by IRF3 dimerization assay (upper panel). Aliquots of the reaction mixtures were analyzed by immunoblotting with a GST antibody (lower
panel). 6KR: GST-RIG-I(N) containing six K > R mutations, including K172R. K172-only: similar to 6KR except that K172 is not mutated.
(B) Mutations at K172 and T55 impair polyUb binding by RIG-I(N) in vitro. GST-RIG-I(N) and mutant proteins were incubated with K63-polyUb chains, then pulled
down with glutathione Sepharose and analyzed by immunoblotting.
(C) Mutations at K172 and T55 impair RIG-I(N)’s ability to induce IFN-b in cells. Different amounts (30 ng and 100 ng) of mammalian expression vectors for GST-
RIG-I(N) and mutants were transfected into HEK293-IFN-b-Luc cells, then luciferase activity was measured. Error bars represent the variation range of duplicate
experiments.
(D) GST-RIG-I(N) and mutant proteins as described in (C) were pulled down with glutathione Sepharose beads, washed with PBS or RIPA buffer, then analyzed by
immunoblotting.
(E) GST-RIG-I(N) was expressed in HEK293T cells, then purified using glutathione Sepharose. The purified protein was treated with isopeptidase T (IsoT) or viral
OTU (vOTU) or mock-treated, then immunoblotted with an antibody against ubiquitin or GST (upper panel; N.S indicates a nonspecific band). Aliquots of the
treated GST-RIG-I(N) were tested for their ability to promote IRF3 dimerization in the reconstitution assay (lower panel).
See also Figure S6.
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than in the cytosol; (3) the majority of viral RNA is in complex with
viral capsid proteins to form ribonucleoprotein particles (RNPs),
and the 50 end of viral RNA can be blocked by viral proteins; (4)
like their mammalian counterparts, most viral mRNAs also
contain 50-cap or other 50-modifications. Thus, RIG-I must be
capable of detecting very tiny amounts of 50-pppRNA that may
be inadvertently or transiently exposed during the course of
viral replication and intracellular trafficking. By reconstituting
RNA-mediated activation of the RIG-I cascade in vitro, we
demonstrate that RIG-I can detect a few 50-pppRNA molecules
(<20 in a cell) in the presence of abundant cellular RNA and
trigger a signaling cascade leading to IRF3 activation. Thus,
our reconstitution system recapitulates the specificity and sensi-
tivity of viral RNA recognition by the RIG-I pathway in cells.RIG-I CARDs Represent a New Type of Ubiquitin Sensor
CARDs are protein interaction domains that play key roles in
many cellular processes including inflammation and apoptosis
(Park et al., 2007). Unexpectedly, we found that the tandem
CARDs of RIG-I bind specifically to K63-linked polyUb chains.
We also found that the tandem CARDs of MDA5, but not the
CARDs of NOD2 or MAVS, bind to K63-polyUb chains (X.J.
and Z.C., unpublished data; Figure S5C). Thus, a subset of
CARDs appears to have the specialized ability to bind K63-poly-
Ub chains. Importantly, mutations that disrupt ubiquitin binding
of RIG-I also impair its ability to activate IRF3, indicating that
polyUb binding plays a key role in RIG-I activation. It will be of
significant interest to identify other CARDs capable of ubiquitin
binding and determine whether proteins harboring these CARDs
require ubiquitin binding for their functions.Polyubiquitin Binding Is Required for RIG-I Activation
An important role of RIG-I ubiquitination in its activation was
suggested based on the observations that K172R mutation of
RIG-I diminishes its ubiquitination and its ability to induce IFN-b
and that the K172-only mutant can induce IFN-b (Gack et al.,
2007). Further supporting this conclusion was the finding that
the T55I mutation, which was known to abrogate IFN-b induction,
also impairs RIG-I ubiquitination (Gack et al., 2008). However,
closer examination of these mutants reveals that K172R and
T55I mutations also impair the ability of RIG-I to bind K63-polyUb
chains (Figure 6B). Moreover, the K172-only mutation reinstalls
polyUb binding by RIG-I, but not ubiquitination of RIG-I
(Figure 6D), implying that polyUb binding but not ubiquitin
modification is required for RIG-I’s function. In support of this
notion, removal of ubiquitin chains from RIG-I with a DUB
(vOTU) had virtually no effect on RIG-I’s activity (Figure 6E).
Most importantly, we demonstrated that unanchored K63-poly-
Ub chains exist in human cells and that these endogenous
chains are potent ligands of RIG-I (Figure 7). Interestingly,
although the RIG-I complex isolated from HEK293T cells
contains both IsoT-sensitive unanchored ubiquitin chains and
IsoT-resistant ubiquitin conjugates, the IsoT treatment com-
pletely abolished the ability of these ubiquitin chains to activate
RIG-I (Figure 7C), strongly suggesting that unanchored polyUb
chains are responsible for RIG-I activation. Although we cannot
rule out the possibility that ubiquitination of some signalingproteins may contribute to RIG-I activation, our data show that
ubiquitinated TRIM25 is incapable of activating RIG-I (Figure S3).Regulation of RIG-I by Endogenous Polyubiquitin Chains
during Viral Infection
We estimated that approximately 10 ng of endogenous K63-Ub6
could be isolated from 20 million HEK293T cells using our
protocol (Figure S7B). This is equivalent to approximately 6000
molecules of K63-Ub6 per cell. These Ub chains activate RIG-I
with an EC50 of approximately 50 pM, which is equivalent to
15 molecules per cell. This estimate, although imprecise,
suggests that there should be abundant endogenous Ub chains
to activate RIG-I(N), explaining why overexpression of RIG-I(N) is
sufficient to induce interferons in the absence of viral infection.
However, in normal cells containing endogenous full-length
RIG-I, which likely adopts an autoinhibited conformation, the
ubiquitin chains cannot gain access to the CARDs of RIG-I and
are rapidly disassembled by high levels of cellular DUB activity.
Viral infection or introduction of 50-pppRNA into the cytosol
presumably induces a conformational change of RIG-I that
exposes the CARDs, which then capture and stabilize unan-
chored K63-polyUb chains synthesized by TRIM25. We specu-
late that local and transient accumulation of these ubiquitin
chains in the vicinity of RNA-bound RIG-I allows the CARDs to
bind these chains, resulting in full activation of RIG-I. However,
as discussed above, only a very small fraction of RIG-I is acti-
vated by viral infection due to limited access to viral RNA in the
cytosol. Nevertheless, we obtained evidence that Sendai virus
infection led to association of IsoT-sensitive ubiquitin chains
with full-length RIG-I (Figures S7C and S7D). Given the high
potency of unanchored K63-ubiquitin chains in RIG-I activation,
accumulation of just a few molecules of these chains in a cell
is likely to activate endogenous RIG-I, provided that a few
molecules of viral RNA are also present.Sequential Binding to RNA and Unanchored
K63-Polyubiquitin Chains Leads to Full
Activation of RIG-I
Our study reveals unanchored K63-polyUb chains as the second
ligand of RIG-I and demonstrates that full activation of RIG-I
requires an orderly binding of viral RNA followed by polyUb
chains. Based on available evidence, we propose a multistep
model of RIG-I activation (Figure 7G). After viral infection, RIG-I
binds to viral 50-pppRNA through its C-terminal RD domain
and may bind to the double-stranded segments of the RNA
through the central helicase domain (Fujita, 2009). The RNA
binding causes dimerization of RIG-I and activates its ATPase
activity (Cui et al., 2008). The energy derived from ATP hydrolysis
propels the translocation of RIG-I along the viral RNA (Myong
et al., 2009). The translocation of RIG-I on viral RNA may help
displace viral proteins from the RNA, facilitating further RIG-I
binding. The translocating RIG-I dimer likely has an ‘‘open’’
conformation that exposes the N-terminal CARDs, which form
a cluster consisting of four CARDs. This cluster of CARDs binds
to K63-polyUb chains. This binding may cause additional confor-
mational changes and/or oligomerization of RIG-I, forming a new
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Figure 7. Endogenous Unanchored K63-Polyubiquitin Chains Activate the RIG-I Pathway
(A) A protocol for isolating functional endogenous polyUb chains in human cells.
(B) Endogenous polyUb chains bound to RIG-I can be released by heat treatment and remain functional. GST-RIG-I(N)-K172-only was expressed in HEK293T
cells and isolated as described in (A), then heated for 5 min at the indicated temperatures. After centrifugation, the supernatant containing heat-resistant ubiquitin
chains was incubated with GST-RIG-I(N) expressed and purified from E. coli (lanes 7–12). The activity of GST-RIG-I(N) was then measured by IRF3 dimerization
assay. As positive controls, K63-polyUb chains were incubated with GST-RIG-I(N)-K172-only, which was then pulled down and heated in parallel experiments
(lanes 1–6). Endo.polyUb: endogenous polyUb.
(C) Endogenous unanchored polyUb chains activate RIG-I(N). PolyUb chains associated with GST-RIG-I(N)-K172-only were captured and released at 75C as in
(B). The heat-resistant supernatant was incubated with GST-RIG-I(N) followed by IsoT treatment (lane 9), or in reverse order (lane 8). As positive controls,
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activation on binding to unanchored K63-ubiquitin chains may
provide another level of regulation of antiviral immune responses.
Unanchored K63-Polyubiquitin Chains
Are Intracellular Signaling Molecules
Our previous study has shown that unanchored polyUb chains
directly activate the protein kinases TAK1 and IKK by binding
to the essential regulatory subunits TAB2 and NEMO, respec-
tively (Xia et al., 2009). We now show that unanchored polyUb
chains bind and activate RIG-I, suggesting that these ubiquitin
chains may have more general functions in cell signaling.
However, unlike TAK1 and IKK activation, which requires very
long polyUb chains, RIG-I can be activated by short K63 chains
consisting of only 3 or 4 ubiquitin moieties. Indeed, K63-Ub4 and
endogenous Ub chains are very potent activators of RIG-I(N)
(Figure 4E and Figure 7F). The clusters of multiple CARDs at
the N termini of RIG-I may bind to K63-ubiquitin chains with
strong affinity and high selectivity. This is in contrast to most
ubiquitin-binding domains, which bind to ubiquitin chains with
weak affinity and low selectivity (Hurley et al., 2006). Our finding
that short ubiquitin chains associate with and potently activate
RIG-I in cells strongly suggests that these are endogenous
ligands of RIG-I. These findings present an unprecedented
example of a biological function of short unanchored ubiquitin
chains and deviate from the paradigm that ubiquitin functions
through covalent conjugation of another protein. It will be of
enormous interest to investigate whether unanchored polyUb
chains regulate other physiological functions besides the RIG-I
and NF-kB pathways.
EXPERIMENTAL PROCEDURES
Biochemical Assay for RIG-I Activation In Vitro
For the standard assay with full-length RIG-I, each ml mixture contained 10 ng
His6-E1, 15 ng Ubc5c, 50 ng His8-TRIM25, 1 mg ubiquitin, indicated amounts of
RNA (200 ng poly(I:C), 30 ng 50-pppRNA [79nt] or 50 ng 50-pppRNA [135nt]),
and 50 to 100 ng His8-RIG-I-Flag in Buffer A (20 mM Tris-HCl [pH 7.5], 2 mM
ATP, 5 mM MgCl2, and 0.5 mM DTT). After incubation at 30
C for 1 hr, 1 ml
of reaction mixture was directly used in IRF3 activation assay as described
in the Extended Experimental Procedures (see also Zeng et al., 2009). For
RIG-I activation assays containing mutant ubiquitin, 1 ml of reaction mixture
was mixed with 10 mg of mitochondrial fraction (P5) in 10 ml Buffer B (20 mM
HEPES-KOH [pH 7.0], 2 mM ATP, 5 mM MgCl2, and 0.25 M D-mannitol) at
30C for 30 min. P5 was then pelleted at 10,000 g for 10 min and washed twice
with Buffer C (20 mM HEPES-KOH at pH 7.4, 0.5 mM EGTA, 0.25 M
D-mannitol, and EDTA-free protease inhibitor cocktail) before it was used for
the IRF3 activation assay.unanchored K63-polyUb chains were incubated with GST-RIG-I(N) and IsoT in se
endogenous polyUb from HEK293T cells was incubated with or without IsoT, the
40 kDa band that is likely K63-Ub6 (see Figure S7B).
(D) Similar to (C), except that the supernatant containing endogenous polyUb cha
antibody or another antibody specific for the K63 linkage of ubiquitin chains.
(E) siRNA oligos targeting GFP (control), TRIM25, or CYLD were transfected into H
encoding GST-RIG-I(N)-K172-only. Endogenous polyUb chains associated with
dimerization assay and visualized by immunoblotting with a ubiquitin antibody. T
(F) Potent activation of RIG-I by endogenous polyUb chains. Different amounts of h
GST-RIG-I(N) to measure IRF3 dimerization. The concentration of the ubiquitin cha
represent the variation range of duplicate experiments.
(G) A proposed mechanism of RIG-I activation by RNA and polyUb (see ResultsFor the standard assay with RIG-I (N), each ml mixture contained 100 ng
GST-RIG-I(N) and 50 to 100 ng ubiquitin chains in a buffer containing 20
mM HEPES-KOH (pH 7.0) and 10% (v/v) glycerol. After incubation at 4C
for 10 min or up to 1 hr, the mixture was directly used in the IRF3 activation
assay.Ubiquitin-Binding Assay
For ubiquitin binding by full-length RIG-I, His8-RIG-I-Flag (1 mg) or the ATPase
mutant (K270A or D372N) was incubated with K63-Ub4 or K63-polyUb (1 mg),
and 50-pppRNA (0.3 mg for 135nt RNA) in 10 ml Buffer A at 4C for 1 hr. For
reactions lacking ATP, EDTA (10 mM) was added. The mixture was then diluted
5-fold in Buffer D (20 mM Tris-HCl [pH 7.5], 100 mM NaCl, 0.5% [w/v] NP-40,
and 10% [v/v] glycerol) and immunoprecipitated with anti-Flag or anti-RIG-I
antibody. The bound proteins were eluted with Flag peptide or SDS sample
buffer and subjected to immunoblotting analysis with antibodies specific for
ubiquitin or RIG-I.
For ubiquitin binding by RIG-I(N), 2 mg of wild-type or mutant GST-RIG-I(N)
was incubated with 1 mg ubiquitin chains in 10 ml buffer containing 20 mM
HEPES-KOH (pH 7.0) and 10% (v/v) glycerol at 4C for 1 hr. The mixture
was then diluted 5-fold in Buffer D before the GST proteins were pulled
down with glutathione Sepharose. The bound proteins were analyzed by
immunoblotting.
To analyze RIG-I(N):K63-Ub4 complex, GST-RIG-I(N) was cleaved with
Tev protease and then RIG-I(N) was purified on Q-Sepharose and Super-
dex-200 columns. Five micrograms each of purified RIG-I(N) and K63-Ub4
were incubated at 4C for 60 min, and then the mixture was separated on
Superdex-200 PC (3.2/30) using the SMART purification system. The elution
buffer contained 20 mM Tris-HCl (pH7.5), 0.1 mM EGTA, 0.5 mM DTT, and
0.02% CHAPS. Aliquots of the fractions were analyzed in the in vitro IRF3
dimerization assay and also by immunoblotting using antibodies against
RIG-I or ubiquitin.Isolation and Functional Analysis of Endogenous
Polyubiquitin Chains
HEK293T cells were transfected in 10 cm dishes with 5 mg of pEF-GST-RIG-
I(N)-K172-only. The cells were lysed 48 hr later in Buffer E (20 mM Tris-HCl
at pH 7.5, 150 mM NaCl, 10% [v/v] glycerol, 1% [w/v] Triton X-100, 20 mM
b-glycerol phosphate, 1 mM Na3VO4, 0.1 mM NaF, 0.1 mM phenylmethanesul-
fonyl fluoride, and EDTA-free protease inhibitor cocktail) supplemented with
10 mM NEM. After centrifugation at 20,000 g for 15 min, 5 mM DTT was added
to the supernatant to quench NEM, then the GST proteins were isolated with
glutathione Sepharose. The proteins on the beads were incubated in 30 ml
Buffer F (20 mM HEPES-KOH at pH 7.0, 10% [v/v] glycerol, and 0.02% [w/v]
CHAPS) at 70C, 75C, or 80C for 5 min. Following a brief centrifugation,
the supernatant containing the dissociated polyUb chains was incubated
with 100 ng of bacterially expressed GST-RIG-I(N) at 4C for 1 hr, followed
by IRF3 dimerization assay. For deubiquitination enzyme treatment, the
heated supernatant was incubated with 10 ng/ml IsoT or CYLD at 30C for
1 hr. The concentration of endogenous polyUb chains was estimated by
semiquantitative immunoblotting using synthetic K63-Ub6 (Boston Biochem)
as the standard (Figure S7B).quential orders as indicated. In the right panel, the heat supernatant containing
n analyzed by immunoblotting with a ubiquitin antibody. The arrow denotes an
ins was treated with CYLD. The ubiquitin chains were detected with a ubiquitin
EK293T cells, which were subsequently transfected with an expression vector
the GST-RIG-I(N) protein were isolated as described in (A), then tested in IRF3
he efficiency of RNAi was also confirmed by immunoblotting.
eat-resistant supernatant containing endogenous polyUb were incubated with
ins was estimated by semiquantitative immunoblotting (Figure S7B). Error bars
and Discussion).
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